Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenjia Sun

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
Frontiers in Immunology|October 3, 2022
A new personalized vaccine strategy based on inducing the pyroptosis of tumor cells <i>in vivo</i> by transgenic expression of a truncated GSDMD N-terminusJinrong He, Peng Zheng, Yongjun Chen, et al.
Respirology (Carlton, Vic.)|April 15, 2026
Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target TrialCan Xia, Wanlong Wu, Saisai Lu, et al.
RMD Open|March 8, 2024
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD ConsortiumLinyi Peng, Jingna Li, Jiaxin Zhou, et al.
The European Respiratory Journal|January 30, 2025
Effectiveness and safety of tofacitinib <i>versus</i> calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort studyWanlong Wu, Bingpeng Guo, Wenjia Sun, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
Frontiers in Immunology|October 3, 2022
A new personalized vaccine strategy based on inducing the pyroptosis of tumor cells <i>in vivo</i> by transgenic expression of a truncated GSDMD N-terminusJinrong He, Peng Zheng, Yongjun Chen, et al.
Respirology (Carlton, Vic.)|April 15, 2026
Upadacitinib Versus Tofacitinib in Anti-MDA5-Positive Dermatomyositis With Interstitial Lung Disease: A Multi-Centre Cohort Study Emulating a Target TrialCan Xia, Wanlong Wu, Saisai Lu, et al.
RMD Open|March 8, 2024
The development and initial validation of IgG4-related disease damage index: a consensus report from Chinese IgG4-RD ConsortiumLinyi Peng, Jingna Li, Jiaxin Zhou, et al.
The European Respiratory Journal|January 30, 2025
Effectiveness and safety of tofacitinib <i>versus</i> calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort studyWanlong Wu, Bingpeng Guo, Wenjia Sun, et al.
Pageof 11